리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 11월
페이지 정보:영문 93 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 연구용 항체 시장은 2030년까지 58억 달러에 달할 전망
2023년에 42억 달러로 추정되는 세계의 연구용 항체 시장은 분석 기간인 2023-2030년에 CAGR 4.9%로 성장하며, 2030년에는 58억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 시약은 CAGR 4.6%를 기록하며, 분석 기간 종료시에는 48억 달러에 달할 것으로 예측됩니다. 항체 부문의 성장률은 분석 기간 중 CAGR 6.4%로 추정됩니다.
미국 시장은 12억 달러로 추정, 중국은 CAGR 4.6%로 성장할 것으로 예측
미국의 연구용 항체 시장은 2023년에 12억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2023-2030년 CAGR 4.6%를 견인하며 2030년까지 10억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.3%와 4.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.
세계의 연구용 항체 시장 - 주요 동향과 촉진요인 정리
과학적 발견에 필수적인 연구용 항체란?
연구용 항체는 특정 단백질에 정확하게 결합하는 능력을 통해 과학자들이 복잡한 생물학적 샘플에서 생체 분자를 검출, 측정 및 조작할 수 있도록 하는 생물학 연구에 필수적인 툴입니다. 이러한 항체는 분자생물학, 면역학, 종양학, 신경과학 등 다양한 분야에서 세포 과정, 신호 전달 경로 및 질병 메커니즘을 조사하는 데 중요한 역할을 합니다. 항체는 웨스턴 블로팅, 면역조직화학(IHC), 효소 결합 면역 흡착법(ELISA) 등의 방법으로 조직 및 세포내 단백질 및 기타 항원을 식별하는 데 사용됩니다. 이러한 특이성과 범용성으로 인해 연구용 항체는 기초 생물학 및 질병 병리학을 이해하는 데 필수적인 역할을 하고 있습니다.
정밀의료와 맞춤 치료의 시대에 분자 수준에서 표적 분석을 가능하게 하는 연구용 항체는 더욱 중요해지고 있습니다. 예를 들어 암 연구에서 항체는 치료 방침을 결정하고 질병의 진행을 모니터링하기 위한 바이오마커를 검출하는 데 자주 사용됩니다. 이러한 상세한 분자 프로파일링을 가능하게 함으로써 연구용 항체는 기초과학과 임상 적용을 모두 지원합니다. 진단 및 치료 의사결정에 있으며, 바이오마커의 중요성이 높아짐에 따라 고품질의 신뢰할 수 있는 항체에 대한 수요가 증가하고 있습니다. 따라서 연구용 항체는 과학적 지식을 심화시킬 뿐만 아니라, 중개 연구 및 임상 연구 적용을 통해 환자 치료 결과를 개선하는 데 필수적인 툴이 되고 있습니다.
기술 혁신은 어떻게 연구용 항체 시장을 형성하고 있는가?
기술의 발전은 연구용 항체의 능력과 용도를 크게 확장하여 보다 특이적이고 안정적이며 재현성이 높은 항체를 개발할 수 있게 되었습니다. 주요 기술 혁신 중 하나는 유전자 복제 및 발현 기술을 사용하여 생산되는 재조합 항체의 개발입니다. 재조합 항체는 기존의 단일 클론 항체와 달리 일관성이 높고 배치 간 편차가 없어 실험적 연구에서 신뢰성이 높습니다. 이러한 일관성은 정확한 분석을 위해 재현성이 필수적인 임상 및 제약 용도에서 특히 가치가 있습니다. 또한 재조합 항체는 표적 항원에 대해 더 높은 특이성과 친밀도를 갖도록 설계할 수 있으므로 표적 외 효과의 가능성을 낮추고 실험 결과의 정확성을 향상시킬 수 있습니다.
또 다른 중요한 기술적 진보는 낙타과 항체에서 유래한 단일 도메인 항체, 즉 '나노 항체'의 출현입니다. 이 나노체는 기존 항체보다 작고 안정성이 높아 생세포 이미징이나 세포내 연구와 같이 기존 항체가 너무 크거나 불안정한 용도에 적합합니다. 나노체는 세포내 표적에 접근하고 결합할 수 있으며, 단백질 상호작용을 실시간으로 연구할 수 있는 새로운 가능성을 열어줍니다. 또한 자동화 및 고처리 스크리닝 기술은 항체 개발 과정을 더 빠르고 효율적으로 만들어 연구자들이 대량의 항체 라이브러리를 스크리닝하여 가장 효과적인 후보를 식별할 수 있도록 돕습니다. 이러한 기술 혁신은 과학자들에게 진화하는 현대의 연구 요구에 부합하는 다양한 툴을 제공함으로써 연구용 항체 시장을 재편하고 있습니다.
연구용 항체 시장에 존재하는 과제와 기회는?
연구용 항체는 과학적 발견에 매우 중요한 역할을 하지만, 시장에서는 제품의 품질과 재현성에 대한 큰 문제에 직면해 있습니다. 가장 큰 문제 중 하나는 시중에서 판매되는 모든 항체가 특이성과 일관성 측면에서 요구되는 기준을 충족하지 못한다는 점입니다. 배치 간 편차 및 불충분한 검증은 신뢰할 수 없는 실험 결과를 초래하는 일반적인 문제이며, 이는 궁극적으로 연구 결과의 신뢰성에 영향을 미칩니다. 또한 비특이적 결합 및 교차 반응성이 존재하면 위양성 및 위음성이 발생하여 데이터 분석이 복잡해집니다. 이러한 문제를 해결하고 과학 연구의 재현성을 보장하기 위해 표준화된 검증 프로토콜과 항체 성능에 대한 투명한 데이터를 요구하는 연구자 및 연구 기관의 목소리가 점점 더 커지고 있습니다.
그러나 이러한 도전은 시장 성장과 혁신의 기회로 작용하고 있습니다. 현재 각 기업은 연구자들에게 제품의 신뢰성을 보장하기 위해 독립적인 제3자 테스트를 포함한 엄격한 품질관리 및 검증 프로세스에 투자하고 있습니다. 또한 특정 연구 요구에 맞는 맞춤형 항체 솔루션에 대한 수요도 증가하고 있습니다. 맞춤형 항체 서비스는 종종 재조합 기술을 통해 연구자 고유의 표적과 용도에 최적화된 항체를 제공합니다. 연구자들이 항체의 높은 수준과 맞춤화를 요구함에 따라 시장은 보다 전문적인 제공과 검증을 강화하는 방향으로 전환하고 있습니다. 또한 더 많은 학술기관과 연구 지원 기관이 재현성을 중요시하는 가운데, 검증되고 신뢰할 수 있는 항체를 제공할 수 있는 기업은 경쟁 우위를 확보할 수 있는 기회를 얻게 될 것입니다.
연구용 항체 시장을 가속화하는 주요 촉진요인은?
연구용 항체 시장의 성장은 생물 의학 연구의 발전과 고품질 연구 툴에 대한 수요 증가를 반영하는 몇 가지 요인에 의해 주도되고 있습니다. 암, 자가면역질환, 감염성 질환과 같은 질병 증가는 주요 촉진요인 중 하나이며, 연구자들은 질병 경로를 연구하고, 바이오마커를 식별하고, 잠재적 치료 표적을 개발하기 위해 항체를 찾고 있습니다. 예를 들어 암 연구에서 항체는 종양의 거동을 이해하고, 예후를 평가하고, 맞춤형 치료를 설계하는 데 도움이 되는 특정 단백질 마커를 식별하는 데 광범위하게 사용되고 있습니다. 약물의 효능을 테스트하고 잠재적인 표적 외 효과를 모니터링하는 데 사용되는 약물 개발에서의 항체 사용 확대도 시장 성장을 가속하는 요인으로 작용하고 있습니다.
또한 학계, 제약사, 정부 기관의 연구개발 투자 확대가 주요 촉진요인으로 작용하고 있습니다. 새로운 치료법과 진단 툴에 대한 수요가 증가함에 따라 생물 의학 연구 자금이 증가하여 연구용 항체 시장이 견고하게 형성되고 있습니다. 또한 신약 개발에서 하이스루풋 스크리닝 기술의 채택이 증가함에 따라 대규모 연구에 사용할 수 있는 신뢰할 수 있는 항체에 대한 수요가 더욱 증가하고 있습니다. 유전체학, 단백질체학 등의 분야가 발전함에 따라 다양한 단백질을 표적으로 삼고 상세한 분자 분석이 가능한 항체에 대한 수요도 증가하고 있습니다. 마지막으로 특히 북미와 유럽과 같은 지역에서는 정부 차원의 생의학 연구 지원 정책이 시장을 강화하고 있으며, 이는 이 분야의 지속적인 성장과 기술 혁신에 기여하고 있습니다.
부문
제품(시약, 항체), 기술(웨스턴 블로팅, 유세포분석, 효소 결합 면역 흡착 측정법(ELISA), 면역조직화학, 면역 형광, 면역 침강, 기타 기술), 용도(종양학, 감염증, 면역학, 줄기세포, 신경 생물학, 기타 용도), 최종 용도(제약·바이오테크놀러지 기업, 학술·연구기관, CRO(임상시험 수탁기관 기관)).
조사 대상 기업의 예(총 42건)
Abcam plc
Active Motif, Inc.
Affinity Biologicals, Inc.
Agilent Technologies, Inc.
BD
Beckman Coulter, Inc.
Bethyl Laboratories, Inc.
Bio SB
BioLegend, Inc.
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Enzo Life Sciences, Inc.
F. Hoffmann-La Roche Ltd
GenScript
Jackson ImmunoResearch Inc.
Lonza
Merck KGaA
Miltenyi Biotec
OriGene Technologies, Inc.
PerkinElmer Inc.
QIAGEN
Rockland Immunochemicals, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장의 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Research Antibodies Market to Reach US$5.8 Billion by 2030
The global market for Research Antibodies estimated at US$4.2 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Antibodies segment is estimated at 6.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.6% CAGR
The Research Antibodies market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.
Global Research Antibodies Market - Key Trends & Drivers Summarized
What Makes Research Antibodies Vital in Scientific Discovery?
Research antibodies are essential tools in biological research, utilized for their ability to precisely bind to specific proteins, allowing scientists to detect, measure, and manipulate biomolecules within complex biological samples. These antibodies play a critical role across various fields, including molecular biology, immunology, oncology, and neuroscience, as they enable researchers to investigate cellular processes, signaling pathways, and disease mechanisms. Antibodies are used in techniques such as Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA), among others, to identify proteins or other antigens in tissues and cells. Their specificity and versatility make research antibodies indispensable for advancing our understanding of fundamental biology and disease pathology.
In the era of precision medicine and personalized therapies, research antibodies have become even more crucial as they allow for targeted analysis at the molecular level. For instance, in cancer research, antibodies are frequently used to detect biomarkers that inform treatment decisions and monitor disease progression. By enabling such detailed molecular profiling, research antibodies support both basic science and clinical applications. With the growing importance of biomarkers in diagnostics and therapeutic decision-making, the demand for high-quality, reliable antibodies is on the rise. This makes research antibodies essential tools not only for advancing scientific knowledge but also for improving patient outcomes through their application in translational and clinical research.
How Are Technological Innovations Shaping the Research Antibodies Market?
Technological advancements have greatly expanded the capabilities and applications of research antibodies, leading to the development of more specific, stable, and reproducible antibodies. One of the major innovations is the development of recombinant antibodies, which are produced using gene cloning and expression techniques. Unlike traditional monoclonal antibodies, recombinant antibodies offer higher consistency and are not subject to batch-to-batch variability, making them more reliable for experimental research. This consistency is particularly valuable in clinical and pharmaceutical applications, where reproducibility is essential for accurate analysis. Additionally, recombinant antibodies can be engineered to have higher specificity and affinity for target antigens, reducing the likelihood of off-target effects and improving the accuracy of experimental results.
Another significant technological advancement is the emergence of single-domain antibodies, or "nanobodies," derived from camelid antibodies. These nanobodies are smaller and more stable than traditional antibodies, making them ideal for applications where traditional antibodies may be too large or unstable, such as in live-cell imaging and intracellular studies. Nanobodies have the potential to access and bind to targets within cells, opening new possibilities for studying protein interactions in real time. Furthermore, automation and high-throughput screening technologies are enabling faster and more efficient antibody development processes, allowing researchers to screen large libraries of antibodies to identify the most effective candidates. These innovations are reshaping the research antibodies market by providing scientists with a wider range of tools tailored to the evolving needs of modern research.
What Challenges and Opportunities Exist in the Research Antibodies Market?
While research antibodies are invaluable to scientific discovery, the market faces significant challenges related to product quality and reproducibility. One of the primary concerns is that not all commercially available antibodies meet the required standards for specificity and consistency. Batch-to-batch variability and inadequate validation are common issues that can lead to unreliable experimental results, ultimately impacting the credibility of research findings. Furthermore, the presence of non-specific binding or cross-reactivity can produce false positives or negatives, complicating data interpretation. Researchers and institutions increasingly call for standardized validation protocols and transparent data on antibody performance to address these issues and ensure reproducibility in scientific research.
However, these challenges have also spurred opportunities for growth and innovation in the market. Companies are now investing in rigorous quality control and validation processes, including independent third-party testing, to assure researchers of the reliability of their products. Additionally, there is an increasing demand for customized antibody solutions tailored to specific research needs. Custom antibody services provide researchers with antibodies that are optimized for their unique targets and applications, often through recombinant techniques. As researchers seek higher standards and customization in antibodies, the market is shifting toward more specialized offerings and enhanced validation. Furthermore, as more academic institutions and research funding bodies emphasize reproducibility, companies that can deliver well-validated and reliable antibodies are poised to gain a competitive advantage.
What Are the Key Drivers Accelerating the Research Antibodies Market?
The growth in the research antibodies market is driven by several factors, reflecting advancements in biomedical research and the rising demand for high-quality research tools. The increasing prevalence of diseases such as cancer, autoimmune disorders, and infectious diseases is one of the primary drivers, as researchers seek antibodies to study disease pathways, identify biomarkers, and develop potential therapeutic targets. In cancer research, for example, antibodies are used extensively to identify specific protein markers that help researchers understand tumor behavior, assess prognosis, and design personalized treatments. The expanding application of antibodies in drug development, where they are used to test drug efficacy and monitor potential off-target effects, is also driving market growth.
Another key driver is the growing investment in research and development by academic institutions, pharmaceutical companies, and government agencies. As the demand for new therapies and diagnostic tools rises, funding for biomedical research has increased, creating a robust market for research antibodies. Additionally, the increasing adoption of high-throughput screening techniques in drug discovery is further boosting the demand for reliable antibodies that can be used in large-scale studies. With advances in fields like genomics and proteomics, there is also a rising need for antibodies that can target a broad range of proteins, enabling detailed molecular analysis. Finally, government policies that support biomedical research, particularly in regions like North America and Europe, have strengthened the market, helping to ensure sustained growth and innovation in the research antibodies sector.
SCOPE OF STUDY:
The report analyzes the Research Antibodies market in terms of US$ Million by the following Application; End-Use; Product; Technology, and Geographic Regions/Countries:
Segments:
Product (Reagent, Antibodies); Technology (Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation, Other Technologies); Application (Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology, Other Applications); End-Use (Pharma & Biotech Companies, Academic & Research Institutions, Contract Research Organizations (CROs))
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
Abcam plc
Active Motif, Inc.
Affinity Biologicals, Inc.
Agilent Technologies, Inc.
BD
Beckman Coulter, Inc.
Bethyl Laboratories, Inc.
Bio SB
BioLegend, Inc.
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Enzo Life Sciences, Inc.
F. Hoffmann-La Roche Ltd
GenScript
Jackson ImmunoResearch Inc.
Lonza
Merck KGaA
Miltenyi Biotec
OriGene Technologies, Inc.
PerkinElmer Inc.
QIAGEN
Rockland Immunochemicals, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Research Antibodies - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Prevalence of Chronic Diseases and Cancer Drives Demand for Research Antibodies in Diagnostics and Therapeutics
Increasing Investment in Biomedical Research Expands Addressable Market for High-quality Research Antibodies
Advancements in Recombinant Antibody Technology Enhance Consistency and Reproducibility, Strengthening Demand
Rising Focus on Precision Medicine Spurs Need for Specific and Customizable Antibody Solutions
Expansion of Proteomics and Genomics Research Drives Adoption of Antibodies for Target Identification and Validation
Increased Use of Antibodies in Drug Discovery Pipelines Propels Demand for Functional and High-affinity Antibodies
Technological Innovations in Antibody Production Streamline Manufacturing and Accelerate Market Growth
Growing Adoption of Antibodies in Diagnostic Assays Expands Market for Disease-specific and Marker-specific Antibodies
Rising Demand for Monoclonal and Polyclonal Antibodies in Academic Research Institutions Supports Market Growth
Emerging Applications of Antibodies in Neuroscience and Immunology Foster Development of Specialized Antibody Products
Increased Collaboration Between Antibody Manufacturers and Pharmaceutical Companies Drives Market Expansion
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Research Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World 7-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Reagent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World 7-Year Perspective for Reagent by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 7: World 7-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Western Blotting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World 7-Year Perspective for Western Blotting by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World 7-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 13: World 7-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World 7-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Immunofluorescence by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World 7-Year Perspective for Immunofluorescence by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Immunoprecipitation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 19: World 7-Year Perspective for Immunoprecipitation by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 25: World 7-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World 7-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 29: World 7-Year Perspective for Stem Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 30: World Recent Past, Current & Future Analysis for Neurobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 31: World 7-Year Perspective for Neurobiology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 35: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 36: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 37: World 7-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 39: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 40: USA Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 41: USA 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 42: USA Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 43: USA 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: USA 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 46: USA Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 47: USA 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
CANADA
TABLE 48: Canada Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 49: Canada 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 52: Canada Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 53: Canada 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 54: Canada Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 55: Canada 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
JAPAN
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 58: Japan Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 59: Japan 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 60: Japan Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 61: Japan 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
CHINA
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 64: China Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 65: China 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 66: China Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 67: China 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: China 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 70: China Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 71: China 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
EUROPE
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 72: Europe Recent Past, Current & Future Analysis for Research Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 73: Europe 7-Year Perspective for Research Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 76: Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 77: Europe 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 78: Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 79: Europe 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
FRANCE
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 82: France Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 83: France 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 84: France Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 85: France 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: France 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 88: France Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 89: France 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
GERMANY
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 90: Germany Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 91: Germany 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Germany 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 94: Germany Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 95: Germany 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 96: Germany Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 97: Germany 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
ITALY
TABLE 98: Italy Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Italy 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 100: Italy Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 101: Italy 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 102: Italy Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 103: Italy 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
UNITED KINGDOM
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 106: UK Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 107: UK 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 108: UK Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 109: UK 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: UK 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 112: UK Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 113: UK 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
REST OF EUROPE
TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 115: Rest of Europe 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Rest of Europe 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 119: Rest of Europe 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 121: Rest of Europe 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
ASIA-PACIFIC
Research Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Asia-Pacific 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 125: Asia-Pacific 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 127: Asia-Pacific 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Asia-Pacific 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030
REST OF WORLD
TABLE 130: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Product - Reagent and Antibodies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 131: Rest of World 7-Year Perspective for Research Antibodies by Product - Percentage Breakdown of Value Revenues for Reagent and Antibodies for the Years 2024 & 2030
TABLE 132: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 133: Rest of World 7-Year Perspective for Research Antibodies by Technology - Percentage Breakdown of Value Revenues for Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Other Technologies for the Years 2024 & 2030
TABLE 134: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by Application - Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of World 7-Year Perspective for Research Antibodies by Application - Percentage Breakdown of Value Revenues for Oncology, Infectious Diseases, Immunology, Stem Cells, Neurobiology and Other Applications for the Years 2024 & 2030
TABLE 136: Rest of World Recent Past, Current & Future Analysis for Research Antibodies by End-Use - Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 137: Rest of World 7-Year Perspective for Research Antibodies by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies, Academic & Research Institutions and Contract Research Organizations (CROs) for the Years 2024 & 2030